JPWO2021020412A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021020412A5
JPWO2021020412A5 JP2021535370A JP2021535370A JPWO2021020412A5 JP WO2021020412 A5 JPWO2021020412 A5 JP WO2021020412A5 JP 2021535370 A JP2021535370 A JP 2021535370A JP 2021535370 A JP2021535370 A JP 2021535370A JP WO2021020412 A5 JPWO2021020412 A5 JP WO2021020412A5
Authority
JP
Japan
Prior art keywords
seq
oligonucleotide consisting
nucleotide sequence
sequence
oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535370A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021020412A1 (US06268490-20010731-C00004.png
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2020/028960 external-priority patent/WO2021020412A1/ja
Publication of JPWO2021020412A1 publication Critical patent/JPWO2021020412A1/ja
Publication of JPWO2021020412A5 publication Critical patent/JPWO2021020412A5/ja
Pending legal-status Critical Current

Links

JP2021535370A 2019-07-30 2020-07-29 Pending JPWO2021020412A1 (US06268490-20010731-C00004.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019140142 2019-07-30
PCT/JP2020/028960 WO2021020412A1 (ja) 2019-07-30 2020-07-29 Murf1を標的とする核酸医薬

Publications (2)

Publication Number Publication Date
JPWO2021020412A1 JPWO2021020412A1 (US06268490-20010731-C00004.png) 2021-02-04
JPWO2021020412A5 true JPWO2021020412A5 (US06268490-20010731-C00004.png) 2023-07-25

Family

ID=74229918

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535370A Pending JPWO2021020412A1 (US06268490-20010731-C00004.png) 2019-07-30 2020-07-29

Country Status (4)

Country Link
US (1) US20220267778A1 (US06268490-20010731-C00004.png)
EP (1) EP4005602A1 (US06268490-20010731-C00004.png)
JP (1) JPWO2021020412A1 (US06268490-20010731-C00004.png)
WO (1) WO2021020412A1 (US06268490-20010731-C00004.png)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
FR2705099B1 (fr) 1993-05-12 1995-08-04 Centre Nat Rech Scient Oligonucléotides phosphorothioates triesters et procédé de préparation.
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
IL135000A0 (en) 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
DE60044241D1 (de) 1999-03-18 2010-06-02 Exiqon As Xylo-lna analoge
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
JP4383176B2 (ja) 2002-02-13 2009-12-16 武 今西 ヌクレオシド類縁体およびそのヌクレオチド類縁体を含むオリゴヌクレオチド誘導体
MXPA05001837A (es) 2002-08-14 2005-04-19 Pharmacia Corp Modulacion de polaridad opuesta de la expresion de la acil-coa sintetasa 1.
PT2284266E (pt) 2002-11-14 2013-12-17 Thermo Fisher Scient Biosciences Inc Siarn contra tp53
US20070141009A1 (en) 2003-01-03 2007-06-21 Shaharyar Khan Sirna mediated post-transriptional gene silencing of genes involved in alopecia
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
FR2894582B1 (fr) * 2005-12-12 2008-02-22 Fabre Pierre Dermo Cosmetique Sirna anti myosine va et depigmentation de la peau
EP2019692B1 (en) 2006-05-05 2014-06-04 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of gccr
ES2611924T3 (es) 2006-10-03 2017-05-11 Arbutus Biopharma Corporation Formulaciones que contienen lípidos
JP5429884B2 (ja) 2007-11-28 2014-02-26 国立大学法人 東京医科歯科大学 内因性カイロミクロンを利用した、標的遺伝子の発現を抑制する核酸のデリバリーシステム
JP2011505798A (ja) 2007-12-07 2011-03-03 サンタリス ファーマ アー/エス Mcl−1を調節するためのRNAアンタゴニスト化合物
ES2605618T3 (es) 2008-03-31 2017-03-15 National Institute Of Advanced Industrial Science And Technology ARN de doble cadena, modificado con lípidos con elevado efecto de interferencia por ARN
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
DK2279254T3 (en) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
JP2010184879A (ja) 2009-02-10 2010-08-26 Univ Of Tokyo 抗筋萎縮剤
WO2011052436A1 (ja) 2009-10-29 2011-05-05 国立大学法人大阪大学 架橋型人工ヌクレオシドおよびヌクレオチド
EP2327783A1 (en) 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
ES2893199T3 (es) 2010-03-29 2022-02-08 Alnylam Pharmaceuticals Inc Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
CA2801342A1 (en) 2010-06-04 2011-12-08 Eric N. Olson Regulation of metabolism by mir-378
AU2011302152B2 (en) 2010-09-15 2015-06-11 Alnylam Pharmaceuticals, Inc. Modified iRNA agents
SG10201912170WA (en) 2011-11-18 2020-02-27 Alnylam Pharmaceuticals Inc Rnai Agents, Compositions And Methods Of Use Thereof For Treating Transthyretin (TTR) Associated Diseases
CA2856289A1 (en) 2011-11-18 2013-05-23 Alnylam Pharmaceuticals, Inc. Modified rnai agents
JP2015502365A (ja) * 2011-12-12 2015-01-22 オンコイミューニン,インコーポレイティド オリゴヌクレオチドのイン−ビボ送達
EP2791335B1 (en) 2011-12-16 2018-11-14 National University Corporation Tokyo Medical and Dental University Chimeric double-stranded nucleic acid
KR20220028183A (ko) 2012-04-25 2022-03-08 사노피 마이크로rna 화합물 및 mir-21 활성 조절 방법
US9163235B2 (en) 2012-06-21 2015-10-20 MiRagen Therapeutics, Inc. Inhibitors of the miR-15 family of micro-RNAs
US20150337002A1 (en) 2013-01-15 2015-11-26 Shionogi & Co., Ltd. Nucleoside and nucleotide having sulfonamide structure
EP2957567B1 (en) 2013-02-18 2019-06-05 Shionogi & Co., Ltd. Nucleoside and nucleotide, having nitrogen-containing hetercycle structure
WO2015105083A1 (ja) 2014-01-07 2015-07-16 塩野義製薬株式会社 アンチセンスオリゴヌクレオチド及び糖誘導体を含む二本鎖オリゴヌクレオチド
EP3137606A4 (en) 2014-05-01 2018-04-25 Larry J. Smith METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
US10264976B2 (en) * 2014-12-26 2019-04-23 The University Of Akron Biocompatible flavonoid compounds for organelle and cell imaging
EP3603648A4 (en) 2017-03-29 2020-12-30 Shionogi & Co., Ltd COMPLEX OF NUCLEIC ACID MEDICINAL AND MULTI-BRANCHED LIPID

Similar Documents

Publication Publication Date Title
CN108136206B (zh) 抗乙型肝炎病毒的组合物和药剂及其用途
JP2005521393A5 (US06268490-20010731-C00004.png)
JP2015523853A5 (US06268490-20010731-C00004.png)
JP2016522674A5 (US06268490-20010731-C00004.png)
JP2018529732A5 (US06268490-20010731-C00004.png)
JP2015518712A5 (US06268490-20010731-C00004.png)
CN116514890A (zh) 用于B型肝炎病毒感染的RNAi剂
JP2015523855A5 (US06268490-20010731-C00004.png)
JP2015519057A5 (US06268490-20010731-C00004.png)
JP2009102380A5 (ja) dsRNAを含む、ウイルス感染又は望ましくない細胞増殖によって媒介されるか又は誘導される病気又は疾患の治療用組成物
JP2016513976A5 (US06268490-20010731-C00004.png)
JP2015518710A5 (US06268490-20010731-C00004.png)
JP2018519835A5 (US06268490-20010731-C00004.png)
JP2009514877A5 (US06268490-20010731-C00004.png)
JP2008283975A5 (US06268490-20010731-C00004.png)
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
JP2009532392A5 (US06268490-20010731-C00004.png)
JP2018507711A5 (US06268490-20010731-C00004.png)
WO2007056829A1 (en) Multitargeting interfering rnas having two active strands and methods for their design and use
JP2015518711A5 (US06268490-20010731-C00004.png)
WO2006117400A3 (en) Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
CN111511914B (zh) 减少PAPD5和PAPD7 mRNA的核酸分子用于治疗乙型肝炎感染
JP2007530431A5 (US06268490-20010731-C00004.png)
JP2017528441A5 (US06268490-20010731-C00004.png)
JP2020532961A5 (US06268490-20010731-C00004.png)